A Randomised, Double-blind (Sponsor Unblinded), Placebo-controlled, Parallel-group, Multicentre Study to Evaluate the Efficacy and Safety of GSK2269557 Administered in Addition to Standard of Care in Adult Subjects Diagnosed With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00007329/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate the efficacy of GSK2269557 administered in addition
to standard of care in adult subjects diagnosed with an acute exacerbation of Chronic
Obstructive Pulmonary Disease (COPD). Additionally study will also assess safety,
tolerability and pharmacokinetic data. The total duration of the study will be 13-14 weeks
including screening, treatment period and a follow up visit. Subjects will receive once daily
study treatment administration starting on Day 1. Study is planned to recruit approximately
120 subjects such that approximately 100 subjects complete the study.
提供机构：
Vivli
创建时间：
2021-08-24
